Charles River Laboratories International's CEO Discusses Q2 2012 Results - Earnings Call Transcript

Charles River Laboratories International, Inc. (CRL)

Q2 2012 Earnings Results Conference

August 8, 2012 08:30 AM ET


James C. Foster - Chairman, CEO, President and Member of Strategic Planning & Capital Allocation Committee

Thomas F. Ackerman - CFO and Corporate EVP

Susan E. Hardy - Corporate Vice President of Investor Relations


Ross Muken - ISI Group Inc., Research Division

David Windley - Jefferies & Company, Inc., Research Division

Garen Sarafian - Citigroup Inc, Research Division

Timothy Evans - Wells Fargo Securities, LLC, Research Division

Douglas Schenkel - Cowen and Company, LLC, Research Division

Tycho Peterson - JP Morgan Chase & Co, Research Division

Gregory Bolan - Sterne Agee & Leach Inc., Research Division

Ricky Goldwasser - Morgan Stanley, Research Division

John Kreger - William Blair & Company L.L.C., Research Division



Ladies and gentlemen, thank you for standing by and welcome to the Charles River Laboratories Second Quarter 2012 Earnings Call and Meeting with Management. At this time, all participants are in a listen-only mode. Later, we will conduct the question-and-answer session. Instructions will be given to you at that time. (Operator Instructions) And as a reminder, today’s conference call is being recorded.

I’d now like to turn the conference over to Susan Hardy, Corporate Vice President of Investor Relations. Please go ahead.

Susan E. Hardy

Thank you. Good morning and welcome to Charles River Laboratories’ Second Quarter 2012 Conference Call and Webcast. This morning, Jim Foster, Chairman, President and Chief Executive Officer; and Tom Ackerman, Executive Vice President and Chief Financial Officer, will comment on our second quarter results and review guidance for 2012. Following their presentations, we will respond to questions.

At approximately 9:30 when the earnings portion of the conference call has concluded, we will continue with presentations by other senior managers. The webcast will continue through the end of these presentations, which should be at approximately 12 noon. There are two slide decks associated with today’s presentation, which are posted on the Investor Relations section of our website at A taped replay of today’s presentations will be available beginning at 2 PM today and can be accessed by calling 800-475-6701. The international access number is 320-365-3844. The access code in either case is 253408. The replay will be available through August 22nd. You may also access an archived version of the webcast on our Investor Relations website.

I'd like to remind you of our Safe Harbor. Any remarks that we may make about future expectations, plans and prospects for the Company constitute forward-looking statements for purposes of the Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by any forward-looking statements as a result of various important factors including, but not limited to, those discussed on our annual report on Form 10-K, which was filed on February 27, 2012, as well as other filings we make with the Securities and Exchange Commission.

During this call, we will be primarily discussing results from continuing operations and non-GAAP financial measures. We believe that these non-GAAP financial measures help investors to gain a meaningful understanding of our core operating results and future prospects, consistent with the manner in which management measures and forecasts the company's performance.

The non-GAAP financial measures are not meant to be considered superior to or a substitute for results of operations prepared in accordance with GAAP. In accordance with Regulation G, you can find the comparable GAAP measures and reconciliations to those GAAP measures on the Financial Relations section of our website through the Financial Reconciliations link.

Now I'll turn this over to Jim Foster.

James C. Foster

Good morning. I’d like to begin by providing a summary of our second quarter results before providing commentary on our business prospects.

We reported sales of $285 million in the second quarter of 2012, due primarily to the negative effect of foreign exchange. Reported sales were approximately 1% lower than the second quarter of ’11. Strong dollar impacted sales by 3%, so on a constant currency basis, the sales increase was approximately 2%.

PCS business delivered a very good performance in the second quarter with sales increasing 3% over the prior-year on a constant currency basis. We were particularly pleased to see a sequential improvement in PCS sales, up $8.3 million or 8% over the first quarter. The increase was driven primarily by the improvement in In-Life sales, both non-GLP and GLP services and also by the BPS business, which you may recall had a weak first quarter.

The strategic partnership which was initiated last November with the global pharma company was a contributor to the In-Life sales growth. RMS segment sales increased 1.2% year-over-year on a constant currency basis, but as expected was sequentially lower than in the first quarter. This was due to a number of factors including the expected seasonal softness in Research Model sales in Europe and Japan, which we noted when we reported our first quarter results.

The operating margin increased 20 basis points from the second quarter of 2011 and improved 170 basis points sequentially to 19.4%. The improvement was driven by the PCS business. Although declining 90 basis points year-over-year sequentially, the PCS margin increased by 420 basis points to 13.1% primarily due to higher sales. The RMS margin benefited from an insurance payment we received related to the 2011 earth quake in Japan and offset a decline due primarily to lower sales of large models.

As a result, the RMS margin was 32.8%, 20 basis points over the prior-year and just 50 basis points below the outstanding first quarter performance. Earnings per diluted share increased by 7.1% in the second quarter of 2012 to $0.75 per share from $0.70 in the second quarter of ’11. The EPS increase was driven primarily by the lower number of shares outstanding.

Read the rest of this transcript for free on

If you liked this article you might like

GoPro, Alteryx, Charles River Labs, Mallinckrodt: 'Mad Money' Lightning Round

GoPro, Alteryx, Charles River Labs, Mallinckrodt: 'Mad Money' Lightning Round

Don't Get Caught on the Wrong Side: Cramer's 'Mad Money' Recap (Wed 11/15/17)

Don't Get Caught on the Wrong Side: Cramer's 'Mad Money' Recap (Wed 11/15/17)

Advanced Micro Devices, Micron Technology, Charles River Labs: 'Mad Money' Lightning Round

Advanced Micro Devices, Micron Technology, Charles River Labs: 'Mad Money' Lightning Round

Profits Trump Economic Weakness: Cramer's 'Mad Money' Recap (Friday 6/2/17)

Profits Trump Economic Weakness: Cramer's 'Mad Money' Recap (Friday 6/2/17)

Parexel Is Discovering the Drugs of the Future

Parexel Is Discovering the Drugs of the Future